Therapy Industry: Alzheimer%s Disease – Pipeline Review, H1 2012

• Publication date: February 2013
• Report size: 292 pages

Alzheimer's Disease – Pipeline Review, H1 2012 What's inside this report? Global Industries Direct’s, 'Alzheimer's Disease - Pipeline Review, H1 2012', provides an overview of the Alzheimer's Disease therapeutic pipeline. This report provides data on the therapeutic development for Alzheimer's Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also rev...

Alzheimer's Disease – Pipeline Review, H1 2012



What's inside this report?



Global Industries Direct’s, 'Alzheimer's Disease - Pipeline Review, H1 2012', provides an overview of the Alzheimer's Disease therapeutic pipeline. This report provides data on the therapeutic development for Alzheimer's Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Alzheimer's Disease. 'Alzheimer's Disease - Pipeline Review, H1 2012' is built using data and information sourced from Global Industries Direct’s proprietary databases, Firms /University websites, SEC filings, investor presentations and featured press releases from firm /university sites and market -specific third party sources, put together by Global Industries Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.



Scope of the Research


- A snapshot of the global therapeutic scenario for Alzheimer's Disease.
- A review of the Alzheimer's Disease products under development by industry players and universities/research institutes based on information derived from industry player and market -specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Alzheimer's Disease pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage new product development featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.



Reasons to buy


- Identify and understand important and diverse types of therapeutics under development for Alzheimer's Disease.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and take over s effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Alzheimer's Disease pipeline depth and focus of Alzheimer's Disease therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and grow business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Therapy Industry in the United States

Table of Contents
Data table of Contents 2
List of Tables 8
List of Figures 12
Introduction 13
Global March kets Direct Report Coverage 13
Alzheimer's Disease Data 14
Therapeutics Development 15
An Overview of Pipeline Products for Alzheimer's Disease 15
Alzheimer's Disease Therapeutics under Development by Firms 17
Alzheimer's Disease Therapeutics under Investigation by Universities/Institutes 29
Late Stage Products 32
Comparative Analysis 32
Mid Clinical Stage Products 33
Comparative Analysis 33
Early Clinical Stage Products 34
Comparative Analysis 34
Discovery and Pre-Clinical Stage Products 35
Comparative Analysis 35
Alzheimer's Disease Therapeutics – Products under Development by Firms 36
Alzheimer's Disease Therapeutics – Products under Investigation by Universities/Institutes 53
Companies Involved in Alzheimer's Disease Therapeutics Development 56
Bristol-Myers Squibb Firms 56
Johnson & Johnson 57
Boehringer Ingelheim GmbH 58
F. Hoffmann-La Roche Ltd. 59
Abbott Laboratories 60
Biogen Idec Inc. 61
NsGene A/S 62
Sanofi-Aventis 63
AstraZeneca PLC 64
Eli Lilly and Firms 65
GlaxoSmithKline plc 66
Genentech, Inc. 67
Merck & Co., Inc. 68
United Biomedical, Inc. 69
Taisho Pharmaceutical Co., Ltd. 70
Euroscreen S.A. 71
Applied NeuroSolutions, Inc. 72
ExonHit Therapeutics SA 73
Avineuro Pharmaceuticals, Inc. 74
Nanotherapeutics, Inc. 75
Senexis Limited 76
November artis AG 77
Samyang Corporation 78
Aphios Corporation 79
EnVivo Pharmaceuticals 80
DECODON GmbH 81
Astellas Pharma Inc. 82
Chiesi Farmaceutici SpA 83
Daewoong Pharmaceutical Co., Ltd. 84
Eisai Co., Ltd. 85
Elan Corporation, plc 86
H Lundbeck A/S 87
Kowa Firms, Ltd. 88
Les Laboratoires Servier 89
October apharma AG 90
Orion Corporation 91
Pfizer Inc. 92
Toyama Chemical Co. Ltd 93
VIVUS, Inc. 94
Hadasit Medical Research Services & Development Ltd 95
Geron Corporation 96
Addex Pharmaceuticals 97
Evotec Aktiengesellschaft 98
Anavex Life Sciences Corp. 99
Amicus Therapeutics, Inc. 100
Ligand Pharmaceuticals Incorporated 101
Lixte Biotechnology Holdings, Inc. 102
BELLUS Health Inc 103
ReGenX Biosciences, LLC 104
Neuren Pharmaceuticals Limited 105
Nymox Pharmaceutical Corporation 106
Osta Biotechnologies Inc. 107
Critical Outcome Technologies Inc. 108
PharmAthene, Inc. 109
ACADIA Pharmaceuticals Inc. 110
ProteoTech, Inc. 111
WhanIn Pharmaceutical Co., Ltd. 112
Phytopharm Plc 113
SYGNIS Pharma AG 114
Prana Biotechnology Limited 115
Biotie Therapies Corp. 116
Transition Therapeutics Inc. 117
Allon Therapeutics Inc. 118
Neurim Pharmaceuticals (1991) Ltd. 119
Samaritan Pharmaceuticals, Inc. 120
Theravance, Inc. 121
Resverlogix Corp. 122
Suven Life Sciences Ltd. 123
Galapagos NV 124
MediPost Co., Ltd. 125
Proximagen Neuroscience plc. 126
Newron Pharmaceuticals S.p.A. 127
Mithridion, Inc. 128
Teikoku Pharma USA, Inc. 129
Oryzon 130
TauRx Therapeutics Ltd 131
Ceregene, Inc. 132
CoMentis, Inc. 133
AC Immune SA 134
Noscira, S.A. 135
Accera, Inc. 136
Sonexa Therapeutics, Inc. 137
Bio-Link 138
D-Pharm Ltd. 139
StemCells, Inc. 140
Probiodrug AG 141
Snowdon Inc. 142
Domain Therapeutics 143
Wellstat Therapeutics Corporation 144
BIOALVO S.A. 145
Metabolic Solutions Development Co. 146
Hawthorn Pharmaceuticals, Inc. 147
Opsona Therapeutics Ltd. 148
BioArctic Neuroscience AB 149
Affichem 150
QR Pharma, Inc. 151
NeuroNascent, Inc. 152
Siena Biotech S.p.A. 153
SeneXta Therapeutics SA 154
KineMed, Inc. 155
Intellect Neurosciences, Inc. 156
Xencor, Inc. 157
Adeona Pharmaceuticals, Inc. 158
Intra-Cellular Therapies, Inc. 159
Targacept, Inc. 160
N-Gene Research Laboratories, Inc. 161
AB Science 162
Vitae Pharmaceuticals, Inc. 163
Krenitsky Pharmaceuticals Inc. 164
Lipopharma 165
Link Medicine Corporation 166
PALUMED S.A. 167
M's Science Corporation 168
NasVax Ltd. 169
Stelic Institute & Co. 170
Baxter Healthcare Corporation 171
aFraxis Inc. 172
Pharnext SAS 173
Heptares Therapeutics Ltd. 174
Signum Biosciences, Inc. 175
ArmaGen Technologies, Inc. 176
BioChromix Pharma AB 177
Archer Pharmaceuticals, Inc. 178
Varinel, Inc. 179
Reviva Pharmaceuticals Inc. 180
RaQualia Pharma Inc. 181
Immune Technologies and Medicine 182
PharmaNeuroBoost N.V. 183
Alzheimer's Disease – Therapeutics Assessment 184
Assessment by Monotherapy Products 184
Assessment by Combination Products 185
Assessment by Route of Administration 186
Assessment by Molecule Type 189
Drug Profiles 192
Bapineuzumab - Drug Profile 192
Product Description 192
Mechanism of Action 192
R&D Progress 192
Solanezumab - Drug Profile 194
Product Description 194
Mechanism of Action 194
R&D Progress 194
Aricept - Drug Profile 196
Product Description 196
Mechanism of Action 196
R&D Progress 196
Vitamin E + Selenium - Drug Profile 198
Product Description 198
Mechanism of Action 198
R&D Progress 198
Aricept Iontophoretic Patch - Drug Profile 200
Product Description 200
Mechanism of Action 200
R&D Progress 200
Thalidomide - Drug Profile 201
Product Description 201
Mechanism of Action 201
R&D Progress 201
Sunphenon EGCg - Drug Profile 202
Product Description 202
Mechanism of Action 202
R&D Progress 202
SK-PC-B70M - Drug Profile 204
Product Description 204
Mechanism of Action 204
R&D Progress 204
Citalopram - Drug Profile 206
Product Description 206
Mechanism of Action 206
R&D Progress 206
Estradiol + Medroxyprogesterone - Drug Profile 207
Product Description 207
Mechanism of Action 207
R&D Progress 207
Alpha-Tocopherol + Namenda - Drug Profile 209
Product Description 209
Mechanism of Action 209
R&D Progress 209
Raloxifene - Drug Profile 211
Product Description 211
Mechanism of Action 211
R&D Progress 211
Doxycycline + Rifampicin - Drug Profile 212
Product Description 212
Mechanism of Action 212
R&D Progress 212
Doxycycline - Drug Profile 213
Product Description 213
Mechanism of Action 213
R&D Progress 213
Rifampin - Drug Profile 214
Product Description 214
Mechanism of Action 214
R&D Progress 214
Valproate - Drug Profile 215
Product Description 215
Mechanism of Action 215
R&D Progress 215
AC-1204 - Drug Profile 216
Product Description 216
Mechanism of Action 216
R&D Progress 216
WIN-026 - Drug Profile 217
Product Description 217
Mechanism of Action 217
R&D Progress 217
Gammagard Liquid - Drug Profile 218
Product Description 218
Mechanism of Action 218
R&D Progress 218
Alzheimer's Disease Therapeutics – Drug Profile Updates 220
Alzheimer's Disease Therapeutics – Discontinued Products 223
Alzheimer's Disease Therapeutics - Dormant Products 230
Alzheimer's Disease – Product Development Milestones 245
Featured News & Press Releases 245
January 24, 2012: Aphios Receives Phase II SBIR Grant From National Institute On Aging For Alzheimer's Disease Research 245
January 23, 2012: Baxter To Initiate Second Phase III Trial Studying GAMMAGARD LIQUID For Treatment Of Alzheimer's Disease 245
January 05, 2012: Targacept Announces December ision By AstraZeneca To Advance AZD1446 In Alzheimer's Disease 246
December 16, 2011: Journal Of Biological Chemistry Endorses Prana's Drug Pipeline Strategy For Treating Neurodegenerative Diseases 246
December 15, 2011: Prana Commences Alzheimer’s Trial Recruitment 247
November 29, 2011: Elan Provides Update On ELND005 248
November 22, 2011: Prana Receives Approval For Phase II Alzheimer's Trial 249
November 14, 2011: Anavex Successfully Completes Phase I Clinical Trial For ANAVEX 2-73 250
November 14, 2011: Prana's PBT2 Reverses Loss Of Synaptic Activity In Neurons 250
November 14, 2011: Probiodrug Announces Top-Line Results Of First Clinical Study Of PQ912 For Treatment Of Alzheimer’s Disease 251
Appendix 252
Methodology 252
Coverage 252
Secondary Research 252
Primary Research 252
Expert Panel Validation 253
Contact Us 253
Disclaimer 253

List of Tables

Number of Products Under Development for Alzheimer's Disease, H1 2012 15
Products under Development for Alzheimer's Disease – Comparative Analysis, H1 2012 16
Number of Products under Development by Firms, H1 2012 18
Number of Products under Development by Firms, H1 2012 (Contd..1) 19
Number of Products under Development by Firms, H1 2012 (Contd..2) 20
Number of Products under Development by Firms, H1 2012 (Contd..3) 21
Number of Products under Development by Firms, H1 2012 (Contd..4) 22
Number of Products under Development by Firms, H1 2012 (Contd..5) 23
Number of Products under Development by Firms, H1 2012 (Contd..6) 24
Number of Products under Development by Firms, H1 2012 (Contd..7) 25
Number of Products under Development by Firms, H1 2012 (Contd..8) 26
Number of Products under Development by Firms, H1 2012 (Contd..9) 27
Number of Products under Development by Firms, H1 2012 (Contd..10) 28
Number of Products under Investigation by Universities/Institutes, H1 2012 30
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 31
Comparative Analysis by Late Stage Development, H1 2012 32
Comparative Analysis by Mid Clinical Stage Development, H1 2012 33
Comparative Analysis by Early Clinical Stage Development, H1 2012 34
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012 35
Products under Development by Firms, H1 2012 36
Products under Development by Firms, H1 2012 (Contd..1) 37
Products under Development by Firms, H1 2012 (Contd..2) 38
Products under Development by Firms, H1 2012 (Contd..3) 39
Products under Development by Firms, H1 2012 (Contd..4) 40
Products under Development by Firms, H1 2012 (Contd..5) 41
Products under Development by Firms, H1 2012 (Contd..6) 42
Products under Development by Firms, H1 2012 (Contd..7) 43
Products under Development by Firms, H1 2012 (Contd..8) 44
Products under Development by Firms, H1 2012 (Contd..9) 45
Products under Development by Firms, H1 2012 (Contd..10) 46
Products under Development by Firms, H1 2012 (Contd..11) 47
Products under Development by Firms, H1 2012 (Contd..12) 48
Products under Development by Firms, H1 2012 (Contd..13) 49
Products under Development by Firms, H1 2012 (Contd..14) 50
Products under Development by Firms, H1 2012 (Contd..15) 51
Products under Development by Firms, H1 2012 (Contd..16) 52
Products under Investigation by Universities/Institutes, H1 2012 53
Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 54
Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 55
Bristol-Myers Squibb Firms, H1 2012 56
Johnson & Johnson, H1 2012 57
Boehringer Ingelheim GmbH, H1 2012 58
F. Hoffmann-La Roche Ltd., H1 2012 59
Abbott Laboratories, H1 2012 60
Biogen Idec Inc., H1 2012 61
NsGene A/S, H1 2012 62
Sanofi-Aventis, H1 2012 63
AstraZeneca PLC, H1 2012 64
Eli Lilly and Firms, H1 2012 65
GlaxoSmithKline plc, H1 2012 66
Genentech, Inc., H1 2012 67
Merck & Co., Inc., H1 2012 68
United Biomedical, Inc., H1 2012 69
Taisho Pharmaceutical Co., Ltd., H1 2012 70
Euroscreen S.A., H1 2012 71
Applied NeuroSolutions, Inc., H1 2012 72
ExonHit Therapeutics SA, H1 2012 73
Avineuro Pharmaceuticals, Inc., H1 2012 74
Nanotherapeutics, Inc., H1 2012 75
Senexis Limited, H1 2012 76
November artis AG, H1 2012 77
Samyang Corporation, H1 2012 78
Aphios Corporation, H1 2012 79
EnVivo Pharmaceuticals, H1 2012 80
DECODON GmbH, H1 2012 81
Astellas Pharma Inc., H1 2012 82
Chiesi Farmaceutici SpA, H1 2012 83
Daewoong Pharmaceutical Co., Ltd., H1 2012 84
Eisai Co., Ltd., H1 2012 85
Elan Corporation, plc, H1 2012 86
H Lundbeck A/S, H1 2012 87
Kowa Firms, Ltd., H1 2012 88
Les Laboratoires Servier, H1 2012 89
October apharma AG, H1 2012 90
Orion Corporation, H1 2012 91
Pfizer Inc., H1 2012 92
Toyama Chemical Co. Ltd, H1 2012 93
VIVUS, Inc., H1 2012 94
Hadasit Medical Research Services & Development Ltd, H1 2012 95
Geron Corporation, H1 2012 96
Addex Pharmaceuticals, H1 2012 97
Evotec Aktiengesellschaft, H1 2012 98
Anavex Life Sciences Corp., H1 2012 99
Amicus Therapeutics, Inc., H1 2012 100
Ligand Pharmaceuticals Incorporated, H1 2012 101
Lixte Biotechnology Holdings, Inc., H1 2012 102
BELLUS Health Inc, H1 2012 103
ReGenX Biosciences, LLC, H1 2012 104
Neuren Pharmaceuticals Limited, H1 2012 105
Nymox Pharmaceutical Corporation, H1 2012 106
Osta Biotechnologies Inc., H1 2012 107
Critical Outcome Technologies Inc., H1 2012 108
PharmAthene, Inc., H1 2012 109
ACADIA Pharmaceuticals Inc., H1 2012 110
ProteoTech, Inc., H1 2012 111
WhanIn Pharmaceutical Co., Ltd., H1 2012 112
Phytopharm Plc, H1 2012 113
SYGNIS Pharma AG, H1 2012 114
Prana Biotechnology Limited, H1 2012 115
Biotie Therapies Corp., H1 2012 116
Transition Therapeutics Inc., H1 2012 117
Allon Therapeutics Inc., H1 2012 118
Neurim Pharmaceuticals (1991) Ltd., H1 2012 119
Samaritan Pharmaceuticals, Inc., H1 2012 120
Theravance, Inc., H1 2012 121
Resverlogix Corp., H1 2012 122
Suven Life Sciences Ltd., H1 2012 123
Galapagos NV, H1 2012 124
MediPost Co., Ltd., H1 2012 125
Proximagen Neuroscience plc., H1 2012 126
Newron Pharmaceuticals S.p.A., H1 2012 127
Mithridion, Inc., H1 2012 128
Teikoku Pharma USA, Inc., H1 2012 129
Oryzon, H1 2012 130
TauRx Therapeutics Ltd, H1 2012 131
Ceregene, Inc., H1 2012 132
CoMentis, Inc., H1 2012 133
AC Immune SA, H1 2012 134
Noscira, S.A., H1 2012 135
Accera, Inc., H1 2012 136
Sonexa Therapeutics, Inc., H1 2012 137
Bio-Link, H1 2012 138
D-Pharm Ltd., H1 2012 139
StemCells, Inc., H1 2012 140
Probiodrug AG, H1 2012 141
Snowdon Inc., H1 2012 142
Domain Therapeutics, H1 2012 143
Wellstat Therapeutics Corporation, H1 2012 144
BIOALVO S.A., H1 2012 145
Metabolic Solutions Development Co., H1 2012 146
Hawthorn Pharmaceuticals, Inc., H1 2012 147
Opsona Therapeutics Ltd., H1 2012 148
BioArctic Neuroscience AB, H1 2012 149
Affichem, H1 2012 150
QR Pharma, Inc., H1 2012 151
NeuroNascent, Inc., H1 2012 152
Siena Biotech S.p.A., H1 2012 153
SeneXta Therapeutics SA, H1 2012 154
KineMed, Inc., H1 2012 155
Intellect Neurosciences, Inc., H1 2012 156
Xencor, Inc., H1 2012 157
Adeona Pharmaceuticals, Inc., H1 2012 158
Intra-Cellular Therapies, Inc., H1 2012 159
Targacept, Inc., H1 2012 160
N-Gene Research Laboratories, Inc., H1 2012 161
AB Science, H1 2012 162
Vitae Pharmaceuticals, Inc., H1 2012 163
Krenitsky Pharmaceuticals Inc., H1 2012 164
Lipopharma, H1 2012 165
Link Medicine Corporation, H1 2012 166
PALUMED S.A., H1 2012 167
M's Science Corporation, H1 2012 168
NasVax Ltd., H1 2012 169
Stelic Institute & Co., H1 2012 170
Baxter Healthcare Corporation, H1 2012 171
aFraxis Inc., H1 2012 172
Pharnext SAS, H1 2012 173
Heptares Therapeutics Ltd., H1 2012 174
Signum Biosciences, Inc., H1 2012 175
ArmaGen Technologies, Inc., H1 2012 176
BioChromix Pharma AB, H1 2012 177
Archer Pharmaceuticals, Inc., H1 2012 178
Varinel, Inc., H1 2012 179
Reviva Pharmaceuticals Inc., H1 2012 180
RaQualia Pharma Inc., H1 2012 181
Immune Technologies and Medicine, H1 2012 182
PharmaNeuroBoost N.V., H1 2012 183
Assessment by Monotherapy Products, H1 2012 184
Assessment by Combination Products, H1 2012 185
Assessment by Stage and Route of Administration, H1 2012 188
Assessment by Stage and Molecule Type, H1 2012 191
Alzheimer's Disease Therapeutics – Drug Profile Updates 220
Alzheimer's Disease Therapeutics – Discontinued Products 223
Alzheimer's Disease Therapeutics – Discontinued Products (Contd..1) 224
Alzheimer's Disease Therapeutics – Discontinued Products (Contd..2) 225
Alzheimer's Disease Therapeutics – Discontinued Products (Contd..3) 226
Alzheimer's Disease Therapeutics – Discontinued Products (Contd..4) 227
Alzheimer's Disease Therapeutics – Discontinued Products (Contd..5) 228
Alzheimer's Disease Therapeutics – Discontinued Products (Contd..6) 229
Alzheimer's Disease Therapeutics – Dormant Products 230
Alzheimer's Disease Therapeutics – Dormant Products (Contd..1) 231
Alzheimer's Disease Therapeutics – Dormant Products (Contd..2) 232
Alzheimer's Disease Therapeutics – Dormant Products (Contd..3) 233
Alzheimer's Disease Therapeutics – Dormant Products (Contd..4) 234
Alzheimer's Disease Therapeutics – Dormant Products (Contd..5) 235
Alzheimer's Disease Therapeutics – Dormant Products (Contd..6) 236
Alzheimer's Disease Therapeutics – Dormant Products (Contd..7) 237
Alzheimer's Disease Therapeutics – Dormant Products (Contd..8) 238
Alzheimer's Disease Therapeutics – Dormant Products (Contd..9) 239
Alzheimer's Disease Therapeutics – Dormant Products (Contd..10) 240
Alzheimer's Disease Therapeutics – Dormant Products (Contd..11) 241
Alzheimer's Disease Therapeutics – Dormant Products (Contd..12) 242
Alzheimer's Disease Therapeutics – Dormant Products (Contd..13) 243
Alzheimer's Disease Therapeutics – Dormant Products (Contd..14) 244

List of Figures

Number of Products under Development for Alzheimer's Disease, H1 2012 15
Products under Development for Alzheimer's Disease – Comparative Analysis, H1 2012 16
Products under Development by Firms, H1 2012 17
Products under Investigation by Universities/Institutes, H1 2012 29
Late Stage Products, H1 2012 32
Mid Clinical Stage Products, H1 2012 33
Early Clinical Stage Products, H1 2012 34
Discovery and Pre-Clinical Stage Products, H1 2012 35
Assessment by Monotherapy Products, H1 2012 184
Assessment by Combination Products, H1 2012 185
Assessment by Route of Administration, H1 2012 186
Assessment by Stage and Route of Administration, H1 2012 187
Assessment by Molecule Type, H1 2012 189
Assessment by Stage and Molecule Type, H1 2012 190